Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.
about
Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancerSystems biology of cisplatin resistance: past, present and futureUsing germline genomics to individualize pediatric cancer treatmentsPharmacogenomics of chemotherapeutic susceptibility and toxicityMixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancerProtein quantitative trait loci identify novel candidates modulating cellular response to chemotherapyGenetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analysesPopulation-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.EPS8 inhibition increases cisplatin sensitivity in lung cancer cells.Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivityAssociation of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationChemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.Relating human genetic variation to variation in drug responses.Methods to analyze big data in pharmacogenomics research.Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.PharmGKB summary: very important pharmacogene information for GSTT1.Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients.Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
P2860
Q26863490-6BC702C1-629C-45E0-97CC-65DF5C2CF231Q26863585-D8062551-3B9B-42C8-9E6C-27B045DCEF73Q27003261-D769CBEB-E4EA-45F3-812C-BE9DD09327CCQ27025558-A7834D50-D846-4BF9-B0D7-7C9EC31BF153Q28480587-43402CDE-AFA9-47C6-A50A-95DB0A10D261Q28541831-2CA3E5B1-702C-49A4-8C22-E2EA116F8B85Q33418358-7607EC58-AA6C-4606-8CD8-E80D994561D7Q33825180-CAFF9301-1D8E-4B35-AA76-E122EB957031Q34459766-E59D7CBA-BE8F-4EBF-959B-F272C38E53A3Q35068272-0D2DE715-2C3B-45BC-AB59-73C4A5CF8A35Q35075274-17F8E016-AE25-4A29-BCAA-55322514C430Q35150207-D97961DC-B6B5-48A3-BFF4-EE108358F4A8Q35741165-0A143F7F-268D-4D6B-B268-8A9409D74E82Q35799841-EB7C297F-BB3F-494A-A454-B15378C21D1CQ36057728-282151A5-B213-478C-8BF6-4BCC214E62ADQ36252524-AD99B97D-985E-4EA6-BD93-5AC67FEE8FAAQ36404935-68BAF047-4714-4A3E-9A51-38CFB1354F0CQ36545157-FA4472BA-FFC7-4F99-9CDE-B588EFC2E067Q37437491-73EE4655-52B2-4FE1-B5F2-451574E4C846Q38909984-CDEB1982-FEFB-4ECD-AB59-7C63A35A9A2BQ38922471-F21DD661-CB15-45A0-BFB3-6DBAC74ABE66Q39321548-5BECAB1E-A124-4CCC-9C61-D92C6E11F1BDQ39790653-419F1EA6-A5B5-4099-90B4-7D373D19BEE7Q41701820-5FE2178A-7385-4102-8FD2-32FB76D64B61Q42235207-862F112E-5C46-4610-8991-D5EED1E30F65Q50900131-8801C64C-C001-466F-BBEA-2533F275C1DFQ55518023-82FB4078-C3C2-48F5-9ADB-8262AEB74ADF
P2860
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Genome-wide meta-analysis iden ...... eptibility across populations.
@en
Genome-wide meta-analysis iden ...... eptibility across populations.
@nl
type
label
Genome-wide meta-analysis iden ...... eptibility across populations.
@en
Genome-wide meta-analysis iden ...... eptibility across populations.
@nl
prefLabel
Genome-wide meta-analysis iden ...... eptibility across populations.
@en
Genome-wide meta-analysis iden ...... eptibility across populations.
@nl
P2093
P2860
P356
P1476
Genome-wide meta-analysis iden ...... eptibility across populations.
@en
P2093
P2860
P2888
P356
10.1038/TPJ.2011.38
P577
2011-08-16T00:00:00Z
P5875
P6179
1023982566